Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression

Maja Puchades, Carol L. Nilsson, Mark Emmett, Kenneth D. Aldape, Yongjie Ji, Frederick F. Lang, Ta Jen Liu, Charles A. Conrad

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.

Original languageEnglish (US)
Pages (from-to)869-875
Number of pages7
JournalJournal of Proteome Research
Volume6
Issue number2
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Galectin 1
Chemotherapy
Glioblastoma
Proteomics
Cells
Association reactions
Tumors
Drug Therapy
Cell Line
Neoplasms
Biomarkers
Therapeutics
Microarray Analysis
Microarrays
Glioma
Transfection
Proteins
Western Blotting
Immunohistochemistry

Keywords

  • Galectin-1
  • Glioblastoma
  • Microarrays
  • Proteomics
  • Western blot

ASJC Scopus subject areas

  • Genetics
  • Biotechnology
  • Biochemistry

Cite this

Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. / Puchades, Maja; Nilsson, Carol L.; Emmett, Mark; Aldape, Kenneth D.; Ji, Yongjie; Lang, Frederick F.; Liu, Ta Jen; Conrad, Charles A.

In: Journal of Proteome Research, Vol. 6, No. 2, 02.2007, p. 869-875.

Research output: Contribution to journalArticle

Puchades, Maja ; Nilsson, Carol L. ; Emmett, Mark ; Aldape, Kenneth D. ; Ji, Yongjie ; Lang, Frederick F. ; Liu, Ta Jen ; Conrad, Charles A. / Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. In: Journal of Proteome Research. 2007 ; Vol. 6, No. 2. pp. 869-875.
@article{55523007aabc44b7be315b3d77085b21,
title = "Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression",
abstract = "Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.",
keywords = "Galectin-1, Glioblastoma, Microarrays, Proteomics, Western blot",
author = "Maja Puchades and Nilsson, {Carol L.} and Mark Emmett and Aldape, {Kenneth D.} and Yongjie Ji and Lang, {Frederick F.} and Liu, {Ta Jen} and Conrad, {Charles A.}",
year = "2007",
month = "2",
doi = "10.1021/pr060302l",
language = "English (US)",
volume = "6",
pages = "869--875",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression

AU - Puchades, Maja

AU - Nilsson, Carol L.

AU - Emmett, Mark

AU - Aldape, Kenneth D.

AU - Ji, Yongjie

AU - Lang, Frederick F.

AU - Liu, Ta Jen

AU - Conrad, Charles A.

PY - 2007/2

Y1 - 2007/2

N2 - Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.

AB - Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.

KW - Galectin-1

KW - Glioblastoma

KW - Microarrays

KW - Proteomics

KW - Western blot

UR - http://www.scopus.com/inward/record.url?scp=33847399649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847399649&partnerID=8YFLogxK

U2 - 10.1021/pr060302l

DO - 10.1021/pr060302l

M3 - Article

VL - 6

SP - 869

EP - 875

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 2

ER -